AURX — Nuo Therapeutics, Inc.

—
OTC · Health Care · Health Care Equipment & Supplies · CIK 1091596 ·
Last close
$1.09
Market Cap
$52.79M
52W High
$2.29
52W Low
$0.77
ADV30
5,183
Next earnings
—
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,866,125 1,192,791 -374,432 -424,928 2,730,205 80,941 4,578,709
Jun 2026 1,768,986 1,170,027 -166,552 -277,601 2,626,290 449,325 4,161,604
Mar 2026 1,302,115 849,727 -446,466 -618,466 1,945,669 263,827 3,329,532
Dec 2025 1,096,830 688,369 -579,338 -578,480 1,845,662 548,946 2,802,221

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,181,027
Investing CF
$-298,746
Financing CF
$1,675,000
CapEx
$-298,746
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.05
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-35,668,229
Inventory
$269,518
Receivables
$1,167,571
ST Investments
—
EBIT TTM
$-1,844,378
Pretax Income TTM
$-2,124,236
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,200,027
EBITDA
$-1,636,984
Free Cash Flow
$-1,647,782
Enterprise Value
$54,153,832
Total Cash
$449,325
Total Debt
$1,810,340
Shares Out
48,433,777
Trailing EPS
$-0.04
Book Value
$-0.03
ROE
—
ROA
-54.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,313,509 -2,516,649 -2,512,216 1,845,662 2,802,221 -956,559 -864,971
Dec 2024 1,365,173 -2,457,835 -2,323,705 1,189,508 675,796 513,712 -2,231,622
Dec 2023 608,525 -3,168,274 -3,171,436 1,877,880 838,732 1,039,148 -3,167,782
Dec 2022 112,250 -3,320,594 -3,171,736 3,047,360 856,022 2,191,338 -3,706,126

TTM Snapshot

Revenues TTM
$5,200,027
NetIncome TTM
$-2,012,466
OpCashFlow TTM
—
Assets (Latest)
$2,626,290
Forward EPS
$-0.01

Peers — same industry

TickerNameMarket CapLastDaily %
COCH Envoy Medical, Inc. $53.20M $6.87 —
HYPR Hyperfine, Inc. $51.10M $0.56 —
RNXT RenovoRx, Inc. $50.18M $1.04 —
POSC POSITRON CORP $55.84M $1.70 —
CNXU Conexeu Sciences Inc. $56.41M $2.00 —

News headlines (Yahoo Finance, 1h cache)

Nuo Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 13:30 · Yahoo
Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
2026-08-17 12:00 · Yahoo
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 21:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.